Transcatheter Aortic Valve Implantation (TAVI) Market Size, Share & Trends Analysis Report By Product (Transfemoral Approach, Transapical Approach), By Applications (Aortic Stenosis, Aortic Regurgitation, Others), By End Use, By Region, and Segment Forecasts - 2035

Transcatheter Aortic Valve Implantation (TAVI) Market Overview

The global transcatheter aortic valve implantation (tavi) market size was valued at USD 9692.26 million in 2025 and is projected to grow from USD 11169.36 million in 2026 to USD 40049.82 million by 2035, at a CAGR of 15.24% from 2026 to 2035.

The transcatheter aortic valve implantation market is moving into a broader stage of structural-heart adoption as treatment expands beyond elderly, inoperable patients toward lower-risk, asymptomatic, redo-valve, and selected aortic regurgitation populations. Contemporary clinical practice strongly favors minimally invasive transfemoral access, which represented about 96.2% of procedures in a large real-world cohort of more than 210,000 patients. Improvements in valve sealing, delivery catheter profiles, repositionability, commissural alignment, coronary access, computed tomography planning, cerebral protection strategies, and tissue durability are strengthening procedure standardization. TAVI patients have also become progressively younger, with contemporary cohorts showing a median age near 79 years compared with substantially older populations during the early commercialization period. Clinical evidence extending beyond 5 years is increasingly important because younger patients require greater confidence regarding structural valve durability, coronary reaccess, pacemaker risk, and the feasibility of future redo-TAVI interventions.

The United States remains the most developed national TAVI market, supported by broad hospital infrastructure, established Heart Team programs, reimbursement coverage, extensive clinical evidence, and high adoption of transfemoral procedures. Annual U.S. TAVR volume had already exceeded 72,000 procedures by 2019, surpassing isolated surgical aortic valve replacement volume, while the global procedure base is now estimated at roughly 200,000 interventions annually. Recent U.S. expansion has been reinforced by the 2025 approval of TAVR for selected patients with asymptomatic severe aortic stenosis and the 2026 approval of the first dedicated transcatheter valve system for symptomatic severe native aortic regurgitation in high-risk patients. At the same time, competitive concentration remains high: Edwards Lifesciences accounted for approximately 66% of the global TAVI device market in recent industry estimates, while Medtronic represented roughly 28%, leaving a smaller but strategically important share for Abbott and emerging valve developers.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: The Transfemoral Approach is expected to remain dominant, supported by contemporary registry evidence showing approximately 96.2% of analyzed TAVI procedures using femoral access as smaller delivery systems improve procedural suitability.
• Leading Application: Aortic Stenosis will continue generating the largest procedural demand, with primary aortic stenosis historically accounting for approximately 91.9% of commercial TAVI cases in a major U.S. registry population.
• Leading Region: North America is expected to lead the market, supported by an established structural-heart ecosystem and the United States already recording more than 72,000 TAVI procedures annually before subsequent indication expansion accelerated adoption.
• Fastest Growing Region: Asia-Pacific is projected to expand fastest as procedure penetration rises from a lower base, with China reporting 9,629 hospital-recorded TAVR procedures in 2023 and continuing to develop domestic valve capacity.
• Technology Trend: Advanced imaging, lower-profile delivery systems, coronary-access optimization, and improved valve positioning are reshaping TAVI, while a 2026 U.S. clearance for dedicated CT-based TAVR planning software illustrates increasing digital integration into procedural workflows.
• Market Driver: Earlier intervention in severe aortic stenosis is becoming a powerful adoption catalyst, as an important randomized study showed a primary outcome event rate of 26.8% with early TAVR versus 45.3% under clinical surveillance.
• Competitive Landscape: Competition remains concentrated around established platforms, with Edwards Lifesciences holding approximately 66% of the global TAVI market and Medtronic about 28%, while smaller manufacturers pursue differentiated designs and geographic expansion.
• Future Outlook: Long-term durability will increasingly determine device selection among younger patients, with 7-year evidence showing bioprosthetic valve failure of approximately 6.9% after TAVR, supporting continued evaluation of lifetime valve-management strategies.

Latest Trends

One of the most important TAVI market trends in 2026 is expansion from symptom-driven treatment toward earlier intervention. Clinical evidence in asymptomatic severe aortic stenosis has materially changed the addressable patient pathway. In a major randomized study, the composite primary endpoint occurred in 26.8% of patients receiving early TAVR compared with 45.3% under clinical surveillance, while unplanned cardiovascular hospitalization occurred in 20.9% and 41.7%, respectively. During a median follow-up of 3.8 years, approximately 87.0% of patients initially assigned to surveillance eventually underwent aortic valve replacement. These findings contributed to the 2025 U.S. indication expansion for the SAPIEN 3 platform in asymptomatic severe aortic stenosis. The shift means structural-heart teams increasingly evaluate disease stage, left ventricular response, biomarker changes, exercise testing, and imaging findings before overt functional deterioration develops, increasing the potential treatment pool beyond the traditional symptomatic severe-disease population.

Another major trend is the transition toward lifetime management of aortic valve disease rather than viewing TAVI as a single procedure. Seven-year follow-up among low-risk patients showed bioprosthetic valve failure rates of approximately 6.9% following TAVR and 7.5% following surgical replacement, highlighting the growing importance of durability data as intervention moves toward patients in their 60s and 70s. Manufacturers are therefore designing frames and delivery systems around coronary reaccess, commissural alignment, future valve-in-valve treatment, reduced paravalvular leakage, and controlled implantation depth. Medtronic received expanded U.S. authorization in 2025 for Evolut systems to treat failed previously implanted transcatheter valves in selected high-risk patients, supporting the emerging redo-TAVI pathway. Artificial intelligence and CT-based planning are also becoming more prominent; dedicated TAVR planning software gained U.S. clearance in May 2026, demonstrating how automated anatomical assessment is becoming integrated into structural-heart workflows.

Market Dynamics

Driver

""Expanding clinical indications are accelerating TAVI adoption across broader patient populations.""

The strongest driver of the Transcatheter Aortic Valve Implantation market is continued expansion of clinical eligibility. TAVI began primarily as an option for patients considered inoperable or at extreme surgical risk but subsequently progressed through high-risk, intermediate-risk, and low-risk populations. Contemporary real-world data involving more than 210,000 patients demonstrate how rapidly the case mix has changed, with median surgical-risk scores falling to approximately 3.3%. The median patient age was about 79 years, and the proportion of patients with bicuspid valve morphology increased from approximately 5.0% to 6.3% between 2019 and 2022. These patterns indicate that TAVI is increasingly embedded in mainstream aortic valve treatment rather than remaining a last-resort intervention.

Earlier treatment of severe disease is creating another layer of demand. In asymptomatic severe aortic stenosis, randomized evidence demonstrated a hazard ratio of approximately 0.50 for the composite of death, stroke, or unplanned cardiovascular hospitalization with early TAVR compared with surveillance. The subsequent expansion of the U.S. indication during 2025 gives Heart Teams a clinically validated pathway for treating selected patients before symptoms become obvious. Aortic regurgitation is also emerging as an additional growth field following the March 2026 U.S. approval of a dedicated transcatheter system for symptomatic severe native aortic regurgitation in patients at high or greater surgical risk, defined in part by predicted 30-day surgical mortality of at least 8%.

Restraint

""Durability, conduction complications, and specialist infrastructure continue to restrict universal adoption.""

Despite favorable adoption, TAVI remains constrained by long-term durability questions, pacemaker implantation, vascular complications, coronary-access considerations, and the requirement for specialized multidisciplinary centers. Historical U.S. registry experience showed permanent pacemaker requirements remaining around 10.8% even as several other outcomes improved. Although modern devices, implantation techniques, cusp-overlap views, and optimized positioning have reduced certain complications, conduction disturbance remains clinically significant because TAVI is moving into younger populations with longer remaining life expectancy. Structural valve deterioration also requires extended surveillance; at 7 years, bioprosthetic valve failure occurred in approximately 6.9% of low-risk TAVR recipients, making durability beyond the first decade increasingly relevant to treatment decisions.

Infrastructure requirements also restrict penetration in emerging markets. European pathway data collected from 202 centers across 37 countries found that 96% of participating centers had on-site cardiac surgery and 81% routinely used a formal Heart Team approach. Those standards illustrate the expertise, imaging capability, catheterization infrastructure, anesthetic support, surgical backup, and post-procedure monitoring required for mature TAVI programs. Geographic inequality remains substantial: European TAVI procedure density reached approximately 189.5 interventions per million people in 2024, while middle-income countries averaged only around 8 procedures per million. Limited reimbursement and fewer trained structural-heart specialists therefore continue to slow widespread adoption outside established cardiovascular systems.

Opportunity

""Emerging markets and new valve-disease indications offer substantial untapped procedural potential.""

Asia-Pacific represents a major opportunity because a large elderly population coincides with comparatively low TAVI penetration. China recorded approximately 9,629 TAVR procedures in monitored hospitals during 2023, close to the 9,928 isolated surgical aortic valve replacements performed during the same period, illustrating how rapidly transcatheter treatment is approaching surgical volumes. Domestic manufacturers including Venus Medtech, MicroPort, JC Medical, and Peijia Medical are strengthening regional availability while global companies are introducing newer-generation systems. In India, Medtronic obtained regulatory approval for Evolut FX+ in June 2025 and commercially introduced the system later that year, while Abbott introduced its Navitor Vision platform in January 2025 with 3 radiopaque markers designed to improve deployment visualization.

Aortic regurgitation provides another important expansion pathway. Traditional TAVI valves were principally optimized for calcified aortic stenosis, where calcium helps anchor the prosthesis, leaving pure native regurgitation technically difficult. The 2026 authorization of a dedicated system for severe symptomatic native aortic regurgitation establishes a new commercial category among patients judged at high or greater surgical risk. This opportunity may expand further as clinical evidence develops for lower-risk regurgitation populations. Valve-in-valve and redo-TAVI procedures provide an additional lifecycle opportunity because thousands of patients implanted during the first decade of commercial TAVI are now entering longer follow-up periods, and 2025 U.S. authorization expanded one major self-expanding platform for treatment within failed transcatheter valves.

Challenge

""Lifetime valve management is becoming more complex as TAVI reaches younger patients.""

The principal strategic challenge is designing an optimal treatment sequence for patients who may require 2 or more valve interventions over their lifetime. TAVI can affect future coronary access, subsequent transcatheter valve implantation, sinus sequestration risk, effective orifice area, and the feasibility of surgical explantation. These concerns are especially important as low-risk patients live considerably longer after their first procedure. Seven-year comparative evidence has shown mean aortic valve gradients of approximately 13.1 mmHg after TAVR versus 12.1 mmHg after surgery, with broadly comparable major composite outcomes. However, treatment decisions increasingly require individualized consideration of annulus size, coronary height, valve type, frame geometry, age, expected longevity, and possible future procedures.

Competitive clinical differentiation is another challenge because new products must demonstrate compelling performance against mature platforms with extensive physician familiarity. Boston Scientific's decision in May 2025 to discontinue the ACURATE product platform globally illustrates the technical and commercial barriers facing challengers. Meanwhile, Edwards Lifesciences and Medtronic together account for roughly 94% of current global TAVI share estimates, creating a demanding benchmark for smaller competitors. New entrants must therefore demonstrate advantages in areas such as paravalvular leak, hemodynamics, pacemaker rates, delivery profile, repositionability, coronary access, durability, or suitability for anatomies that are inadequately served by established systems.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Transcatheter Aortic Valve Implantation market can be assessed by procedural approach and clinical application, with adoption heavily concentrated in minimally invasive transfemoral intervention and severe aortic stenosis treatment. Contemporary practice has moved decisively toward percutaneous access as delivery profiles have become smaller and vascular closure technology has improved. In a large modern registry cohort, approximately 96.2% of analyzed procedures used transfemoral access, while historical transapical utilization declined from double-digit levels during the early TAVI era to well below 1% in mature U.S. practice. By application, aortic stenosis continues to account for the majority of implantation procedures, although aortic regurgitation is positioned for faster percentage growth following the introduction of dedicated transcatheter technology in 2026.

By Types

Transfemoral Approach: The Transfemoral Approach is estimated to account for approximately 96% of procedures within the supplied two-type segmentation framework in mature markets. This approach has become standard because it avoids thoracotomy, facilitates conscious sedation, enables shorter hospital stays, and supports rapid mobilization. Contemporary U.S. data involving more than 202,000 transfemoral cases demonstrate its dominant clinical position. Historical comparisons illustrate the scale of the transition: femoral access increased from approximately 57.1% during the early commercial period to about 95.3% by 2019, while more recent analytical cohorts reached 96.2%. Smaller sheath sizes, improved catheter steerability, percutaneous closure devices, better CT-based vascular screening, and lower-profile valve systems are expected to keep this segment above 90% of eligible procedures through much of the forecast period.

Transapical Approach: The Transapical Approach is estimated to represent approximately 4% within the supplied two-type analytical framework, although its actual share in mature contemporary practice is considerably smaller because other alternative-access methods have increasingly replaced it. Historical U.S. data show transapical access falling from approximately 34.2% in the earliest TAVI period to only about 0.29% by 2019. The method requires direct access through the left ventricular apex and generally involves more invasive procedural management than transfemoral implantation. It may still be considered in highly selected patients where peripheral arterial anatomy prevents femoral access and other alternatives are unsuitable, but improvements in transaxillary, transcaval, and other catheter-based pathways have reduced its clinical importance. As a result, the Transapical Approach is expected to remain a specialist niche rather than a growth engine through 2035.

By Applications

Aortic Stenosis: Aortic Stenosis is estimated to represent approximately 91% of current demand within the supplied application structure and will remain the dominant TAVI indication. Historical commercial registry data showed primary aortic stenosis accounting for approximately 91.9% of procedures, confirming the disease's central role in valve implantation. Aging populations are expanding the diagnosed severe aortic stenosis pool, while treatment eligibility has moved from inoperable patients through low-risk candidates and, beginning in 2025 in the United States, into selected asymptomatic severe disease. In the EARLY TAVR population, clinical surveillance resulted in 41.7% unplanned cardiovascular hospitalization compared with 20.9% after early intervention, reinforcing interest in treating severe disease before functional deterioration. Ongoing trials involving moderate aortic stenosis may create a further addressable group if future evidence supports intervention before disease becomes severe.

Aortic Regurgitation: Aortic Regurgitation is estimated to hold approximately 3% of current demand but is expected to record the fastest application growth from a comparatively small base. Pure native aortic regurgitation historically presented anchoring challenges because affected valves may lack the heavy calcification commonly found in aortic stenosis. The regulatory environment changed materially in March 2026 when a dedicated transcatheter heart valve system received U.S. approval for symptomatic severe native tricuspid aortic regurgitation in patients considered at high or greater risk for surgical replacement. The approved risk framework includes predicted 30-day surgical mortality of at least 8%, creating a defined population for initial commercialization. Dedicated leaflet-engagement designs may gradually expand treatment beyond off-label use and encourage additional competitors to develop regurgitation-specific platforms.

Others: Others are estimated to account for approximately 6% of application demand and primarily capture complex situations such as failed bioprosthetic valves, mixed valve disease, and other Heart Team-selected transcatheter treatment scenarios within the supplied segmentation structure. Historical registry experience showed failed bioprosthetic valves accounting for approximately 4.25% of commercial procedures by 2019, up from approximately 1.12% in the earliest period. This category is expected to gain importance as the installed population of surgical and transcatheter bioprosthetic valves ages. Expanded redo-TAVI authorization granted in 2025 allows selected high-risk patients with failed transcatheter valves to receive another transcatheter prosthesis, strengthening lifetime-management pathways and increasing the strategic value of frame design, coronary accessibility, and compatibility between first and subsequent valves.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 48% of global TAVI activity and is expected to maintain the largest regional position through much of the forecast period. The United States has one of the world's deepest structural-heart infrastructures, with TAVR available across all 50 states and annual procedure volume already reaching 72,991 cases in 2019. The region benefits from broad cardiology referral networks, high CT imaging availability, specialized Heart Teams, mature reimbursement pathways, and rapid integration of clinical-trial evidence into treatment guidelines. Contemporary U.S. practice is overwhelmingly transfemoral, with a large registry cohort showing 96.2% femoral access and a median patient age of approximately 79 years.

North American growth is increasingly supported by indication expansion rather than first-time adoption of TAVI technology. The U.S. became the first major market to authorize a TAVI platform for asymptomatic severe aortic stenosis in 2025 following randomized evidence showing a 26.8% primary endpoint rate with early TAVR versus 45.3% with surveillance. In March 2026, the region also gained the first dedicated U.S.-approved transcatheter system for selected patients with severe native aortic regurgitation. Competitive intensity remains high: recent estimates place Edwards Lifesciences near 75% of the U.S. TAVI market, while Medtronic retains the largest competing position and Abbott continues developing Navitor adoption.

Europe

Europe is estimated to represent approximately 30% of global TAVI demand and remains one of the most sophisticated regions for structural-heart intervention. European procedure density reached approximately 189.5 TAVI procedures per million people in 2024, although substantial variation exists between countries. France recorded around 307.3 procedures per million in 2024, while Germany recorded approximately 311.8 per million in its latest available annual dataset. Italy reached about 222.6 per million, Denmark 217.9, and Sweden 191.5, demonstrating strong penetration across several established national programs. The region benefits from experienced operators, national valve registries, comprehensive public health systems, and broad access to multiple transcatheter valve platforms.

A 2025 European pathway survey covering 202 centers across 37 countries captured 44,089 TAVI procedures performed during 2024, equivalent to an average of approximately 218 interventions per responding center. About 81% of the centers reported using a Heart Team approach, 96% had on-site cardiac surgery, and 54% operated dedicated Heart Valve Clinics. Approximately 64% of centers commonly used age 75 or older as a threshold favoring TAVI, while another 26% used age 80 or older. Future European expansion will be driven by earlier disease detection, broader regional access, lifetime valve planning, growing redo procedures, and continued adoption in Central and Eastern Europe where penetration remains below leading Western European countries.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 18% of the global market and is expected to be the fastest-growing region through 2035. China, Japan, India, South Korea, and Australia are developing distinct TAVI ecosystems, with China combining a large potential patient pool with an expanding group of domestic valve manufacturers. Hospitals included in China's national monitoring system recorded approximately 9,629 TAVR procedures in 2023 compared with 9,928 isolated surgical aortic valve replacements. These figures demonstrate that TAVI has already reached procedural scale despite penetration remaining substantially below the levels found in the United States and several Western European countries.

Competitive expansion is accelerating across the region. Medtronic's Evolut FX+ obtained Indian authorization in June 2025, while Abbott launched Navitor Vision in India in January 2025 with 3 radiopaque deployment markers. Japan also remains a technologically advanced TAVI market, supported by a rapidly aging population and established reimbursement. China is differentiated by domestic companies including Venus Medtech, MicroPort, JC Medical, and Peijia Medical, which are building broader portfolios and reducing dependence on imported technology. With more than 2.6 million valvular-heart-disease hospital admissions recorded in China during 2023 and aortic disease accounting for approximately 26% of those admissions, the long-term addressable population remains significant.

Latin America

Latin America is estimated to represent approximately 2% of global TAVI demand, with Brazil, Mexico, Argentina, Colombia, and selected private hospital networks accounting for much of current adoption. Penetration remains constrained by reimbursement variability, uneven access to advanced cardiac centers, imported-device costs, and a concentration of structural-heart expertise in major metropolitan areas. Nevertheless, demographic aging and improved diagnosis are increasing the number of patients being evaluated for catheter-based treatment. Where comprehensive Heart Teams are available, the clinical appeal of a procedure in which more than 95% of mature-market cases can use transfemoral access supports continued migration away from open surgery for appropriately selected elderly or higher-risk individuals.

The region offers meaningful expansion potential because current procedure density remains far below the approximately 189.5 procedures per million observed across Europe in 2024. Private insurance systems and centers of excellence are likely to lead adoption initially, followed by broader public reimbursement as local outcomes data strengthen. Training partnerships, regional physician education, expanded CT planning capability, and lower-profile delivery systems should reduce procedural barriers. Competitive entry from additional manufacturers could also improve availability, although established companies retain advantages from global evidence bases involving hundreds of thousands of TAVI patients and long-term clinical follow-up extending to 7 years and beyond.

Middle East & Africa

Middle East & Africa is estimated to account for approximately 2% of global TAVI demand, with the Gulf states, Israel, Turkey, South Africa, and selected North African centers forming the principal treatment clusters. Adoption varies dramatically: Israel recorded approximately 238.8 TAVI procedures per million people in recent European cardiovascular datasets, whereas Morocco recorded only around 2.7 per million and Egypt approximately 4.0 per million in the latest available years. This more than 50-fold variation illustrates how healthcare investment, reimbursement, specialist availability, referral pathways, and catheterization infrastructure determine regional access.

Future growth is likely to concentrate in countries investing heavily in tertiary cardiovascular centers and medical technology. Gulf healthcare systems are increasingly developing structural-heart programs capable of treating complex patients locally rather than relying on overseas referrals. However, the requirement for multidisciplinary Heart Teams and procedural backup remains a barrier because approximately 96% of centers participating in a contemporary European TAVI survey had on-site cardiac surgery. Wider adoption across Africa will therefore depend not only on valve availability but also on imaging infrastructure, specialist training, follow-up systems, and sustainable reimbursement. As the global procedure base approaches roughly 200,000 cases annually, manufacturers increasingly view underserved emerging regions as a long-term expansion opportunity.

List of Top Transcatheter Aortic Valve Implantation (TAVI) Companies

• Edwards Lifesciences
• Medtronic
• Abbott
• Boston Scientific
• Venus Medtech
• MicroPort
• JC Medical
• Meril Life Sciences
• Peijia Medical
• JenaValve Technology (Clinical-stage)
• Bracco (HLT) (Clinical-stage)

Top 2 Companies Market Share

Edwards Lifesciences: Edwards Lifesciences is estimated to hold approximately 66% of the global TAVI market and around 75% of the United States market, positioning its SAPIEN platform as the leading balloon-expandable transcatheter valve family. Its competitive strength is supported by extensive clinical evidence, global commercialization across more than 75 countries, and continued development of the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA systems. The company gained an important U.S. indication expansion in May 2025 for selected patients with asymptomatic severe aortic stenosis. Seven-year low-risk data also provide longer-term evidence relevant to younger candidates, showing valve failure of approximately 6.9% following TAVR and helping clinicians evaluate durability alongside surgical replacement.

Medtronic: Medtronic is estimated to account for approximately 28% of the global TAVI market, making it the second-largest supplier and the principal competitor to Edwards Lifesciences. Its Evolut family uses a self-expanding supra-annular design and has established a particularly important clinical position in patients with smaller aortic annuli where effective orifice area and transvalvular gradient are important considerations. In August 2025, the Evolut PRO+, FX, and FX+ systems received expanded U.S. authorization for selected patients requiring treatment of a failed transcatheter aortic valve and facing high or greater surgical risk. Evolut FX+ also expanded geographically, including authorization in India in June 2025, strengthening competition in faster-growing Asia-Pacific markets.

Investment Analysis

Investment in the TAVI sector is increasingly directed toward platforms capable of extending transcatheter treatment beyond conventional severe calcific aortic stenosis. The most strategically important areas include asymptomatic disease, moderate aortic stenosis, native aortic regurgitation, bicuspid anatomy, redo-TAVI, small annuli, improved tissue durability, and procedural planning technologies. The global procedure base is estimated near 200,000 TAVI interventions annually, while penetration still varies from around 190 procedures per million population in high-income European environments to approximately 8 per million across middle-income countries represented in cardiovascular datasets. This gap creates a long-term infrastructure investment opportunity involving structural-heart catheterization laboratories, CT imaging, Heart Valve Clinics, proctoring networks, physician training, and post-implant surveillance. Hospital investment also benefits from procedural simplification, because contemporary transfemoral TAVI can support shorter treatment pathways than open surgical replacement.

Capital allocation is also shifting toward technologies that improve the economics and predictability of lifetime valve care. A patient receiving TAVI at age 65 may require another intervention after 10 or more years, making future coronary access and redo-valve compatibility increasingly relevant at the initial implant. Long-term evidence has therefore become a significant competitive asset; 7-year low-risk follow-up has reported valve failure rates below 8% for both transcatheter and surgical bioprostheses in a major randomized population. Companies capable of combining valve innovation with imaging software, delivery technologies, cerebral protection, automated planning, or post-procedure analytics may gain additional strategic value. The May 2026 U.S. clearance of dedicated CT software for TAVR planning demonstrates how investment is expanding beyond the valve itself into a broader digital structural-heart ecosystem.

New Product Development

New product development is focused on precision deployment, coronary access, smaller delivery systems, durability, sealing, and treatment of anatomies historically considered difficult for TAVI. Medtronic's Evolut FX+ incorporates larger frame windows intended to facilitate coronary access while retaining the self-expanding characteristics of the Evolut platform. Abbott's Navitor Vision incorporates 3 radiopaque markers to improve visualization during implantation, while the Navitor platform emphasizes controlled delivery and sealing technology. Edwards Lifesciences continues developing the SAPIEN platform around its RESILIA tissue technology and has expanded clinical investigation into earlier-stage aortic stenosis. These product strategies reflect a major shift: with transfemoral access already exceeding 95% in mature practice, manufacturers increasingly differentiate through implantation accuracy, hemodynamics, conduction outcomes, coronary compatibility, and long-term valve management rather than access route alone.

Aortic regurgitation is developing into a particularly important innovation category. Unlike calcific stenosis, native regurgitation may provide insufficient calcium for conventional transcatheter valve anchoring, creating risks of migration and residual leakage. A dedicated transcatheter heart valve system received U.S. approval in March 2026 for symptomatic severe native tricuspid aortic regurgitation in selected high-risk patients, establishing a new treatment pathway and encouraging further research into anchoring technologies. Redo-TAVI is another development priority after expanded authorization during 2025 for implantation within failed transcatheter valves in appropriately selected high-risk patients. Software is also becoming part of product development: CT-based automated TAVR planning technology received U.S. clearance in May 2026, reflecting increased use of digital tools to standardize measurements and support complex anatomical decision-making.

Five Recent Developments

• March 2026: A dedicated transcatheter heart valve system received U.S. approval for symptomatic severe native tricuspid aortic regurgitation in patients considered at high or greater surgical risk, including a surgical mortality threshold of at least 8% at 30 days.
• May 2026: Dedicated CT-based TAVR planning software received U.S. regulatory clearance, strengthening the integration of automated anatomical assessment into structural-heart workflows and supporting more standardized valve sizing, access evaluation, and pre-procedure planning for complex patients.
• August 2025: Medtronic received expanded U.S. authorization for Evolut PRO+, Evolut FX, and Evolut FX+ systems in selected patients with failed transcatheter aortic valves who face high or greater surgical risk, extending the clinical role of redo-TAVI.
• May 2025: Edwards Lifesciences received expanded U.S. approval for the SAPIEN 3 platform in selected asymptomatic severe aortic stenosis patients after randomized evidence showed a 26.8% primary endpoint rate with early TAVR compared with 45.3% under surveillance.
• January 2025: Abbott introduced Navitor Vision in India for high- or extreme-risk patients with symptomatic severe aortic stenosis, incorporating 3 large radiopaque markers designed to improve visualization and support more precise valve positioning during TAVI procedures.

Report Coverage

This report evaluates the Transcatheter Aortic Valve Implantation market across product approach, clinical application, geography, competitive positioning, innovation, investment activity, and recent industry developments over the 2026-2035 forecast period. The analysis focuses exclusively on the supplied product categories of Transfemoral Approach and Transapical Approach and the supplied applications of Aortic Stenosis, Aortic Regurgitation, and Others. Contemporary clinical practice indicates that transfemoral implantation represents approximately 96% of analyzed procedures in mature TAVI programs, while aortic stenosis continues to account for more than 90% of established commercial procedural demand. The report also examines the transition from traditional high-risk treatment toward low-risk, asymptomatic, redo-valve, and selected native regurgitation populations, alongside the growing influence of CT planning, advanced delivery platforms, coronary-access optimization, and long-term durability evidence.

Geographic coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with analysis reflecting significant differences in procedure density, specialist infrastructure, reimbursement, and adoption maturity. Europe currently performs more than 100,000 TAVI procedures annually, while a recent 202-center pathway study captured 44,089 procedures in 2024 alone and reported that 81% of participating centers used a formal Heart Team. Competitive assessment covers Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, Venus Medtech, MicroPort, JC Medical, Meril Life Sciences, Peijia Medical, JenaValve Technology, and Bracco (HLT). With the overall market projected to expand at 15.24% annually from 2026 through 2035, competitive success is expected to depend increasingly on durable clinical outcomes, broader indications, procedural simplicity, geographic access, and the ability to support patients across multiple potential valve interventions over their lifetime.